enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Donanemab – what we know about the latest Alzheimer’s drug

   www.aol.com/donanemab-know-latest-alzheimer-drug...

   Donanemab is given to patients via an intravenous drip once every four weeks. Lilly has said that some patients can complete their course of treatment in as little as six months once their amyloid ...

3. US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10

   www.aol.com/news/us-fda-panel-discuss-eli...

   Lilly's donanemab, administered via once-a-month infusions, is designed to clear a toxic Alzheimer's-linked protein called beta amyloid from the brain. In clinical trials, the treatment slowed the ...

4. A New Alzheimer’s Drug May Be the Most Effective One Yet - AOL

   www.aol.com/alzheimer-drug-may-most-effective...

   About 17% of the patients in the company’s studies no longer showed visible amyloid in their brain scans after six months, about 47% at 12 months and 69% at 18 months. Donanemab has another ...

5. Donanemab - Wikipedia

   en.wikipedia.org/wiki/Donanemab

   Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.

6. Third FDA-approved Alzheimer's drug can give patients more ...

   www.aol.com/news/third-fda-approved-alzheimers...

   The drug, donanemab, was developed by pharmaceutical company Eli Lilly and is marketed under the name Kinusla. It was approved on July 2 and is the third infusion-based drug to slow symptoms, said ...

7. FDA approves Alzheimer’s treatment that has been shown to ...

   www.aol.com/news/fda-approves-alzheimer...

   The Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people with ...

8. Everything we know about breakthrough Alzheimer’s drug Donanemab

   www.aol.com/everything-know-breakthrough...

   The study, published in the Journal of the American Medical Association, concluded that after 76 weeks of treatment, Donanemab was able to slow clinical decline by 35.1% in people with early ...

9. In an unusual move, FDA postpones approval decision for Lilly ...

   www.aol.com/news/unusual-move-fda-postpones...

   Lilly applied to the FDA for approval of the drug in July, after late-stage clinical trial data showed it slowed the progression of Alzheimer’s by 29% after 18 months, compared to a placebo.